LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

Vertex Pharmaceuticals Inc

Suletud

SektorTervishoid

400.63 2.52

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

390.05

Max

401.42

Põhinäitajad

By Trading Economics

Sissetulek

387M

1B

Müük

195M

3B

P/E

Sektori keskmine

27.771

35.733

Aktsiakasum

4.06

Kasumimarginaal

34.84

Töötajad

6,100

EBITDA

641M

1.4B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+25.91% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

3. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-21B

100B

Eelmine avamishind

398.11

Eelmine sulgemishind

400.63

Uudiste sentiment

By Acuity

54%

46%

308 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. aug 2025, 00:05 UTC

Kuumad aktsiad

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4. aug 2025, 21:21 UTC

Tulu
Suurimad hinnamuutused turgudel

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4. aug 2025, 20:45 UTC

Tulu

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

5. mai 2025, 21:00 UTC

Tulu

Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge

5. aug 2025, 20:44 UTC

Tulu

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. aug 2025, 18:17 UTC

Tulu

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. aug 2025, 15:25 UTC

Tulu

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5. aug 2025, 14:12 UTC

Tulu

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5. aug 2025, 11:27 UTC

Tulu

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. aug 2025, 10:55 UTC

Tulu

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. aug 2025, 10:36 UTC

Tulu

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. aug 2025, 10:18 UTC

Tulu

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

4. aug 2025, 20:15 UTC

Tulu

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4. aug 2025, 20:13 UTC

Tulu

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

6. mai 2025, 16:31 UTC

Tulu

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

5. mai 2025, 20:03 UTC

Tulu

Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX

5. mai 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 1Q Net $646.3M >VRTX

5. mai 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX

5. mai 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX

5. mai 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX

27. apr 2025, 11:00 UTC

Peamised uudised

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

11. apr 2025, 09:30 UTC

Peamised uudised

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

Vertex Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

25.91% tõus

12 kuu keskmine prognoos

Keskmine 492.35 USD  25.91%

Kõrge 624 USD

Madal 405 USD

Põhineb 24 Wall Streeti analüütiku instrumendi Vertex Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

24 ratings

14

Osta

10

Hoia

0

Müü

Tehniline skoor

By Trading Central

428.545 / 498.65Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

308 / 371 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.